중동 및 아프리카 위암 진단 시장 – 2030년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

중동 및 아프리카 위암 진단 시장 – 2030년까지의 산업 동향 및 예측

  • Healthcare IT
  • Published Report
  • Mar 2023
  • MEA
  • 350 Pages
  • 테이블 수: 160
  • 그림 수: 56

Middle East And Africa Gastric Cancer Diagnostics Market

시장 규모 (USD 10억)

연평균 성장률 :  % Diagram

Diagram 예측 기간
2024 –2030
Diagram 시장 규모(기준 연도)
백만 달러
Diagram 시장 규모(예측 연도)
미국 달러 69.63
Diagram 연평균 성장률
%
Diagram주요 시장 플레이어
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>중동 및 아프리카 위암 진단 시장, 제품 유형(기구, 시약 및 소모품, 서비스), 진단 유형(확인 검사, 위암 선별 검사/신체 검사), 연령대(성인, 소아 및 노인), 질병 유형(장 또는 확산성 선암, 카르시노이드 종양, 위장관 기질 종양 (GIST), 위 림프종 및 기타), 병기(0기, 1기, 2기, 3기), 성별(남성 및 여성), 샘플 유형(혈액, 조직, 소변 및 대변), 최종 사용자(진단 실험실, 병원, 암 연구소, 종양 전문 클리닉 및 기타), 유통 채널(직접 입찰 및 소매 판매) - 업계 동향 및 2030년까지의 예측.

중동 및 아프리카 위암 진단 시장

중동 및 아프리카 위암 진단 시장 분석 및 통찰력

중동과 아프리카의 노령 인구 증가는 위암 진단 산업의 성장을 주도하고 있습니다. 위장관 종양과 림프종의 유병률도 위암 진단에 대한 수요를 촉진했습니다. 주요 시장 제약은 개발도상국도 혜택을 볼 수 있도록 암 진단 검사와 관련된 높은 가격을 낮춰야 한다는 필요성입니다.

중동 및 아프리카 위암 진단 시장중동 및 아프리카 위암 진단 시장

수많은 시장 참여자들이 중동 및 아프리카 위암 진단 시장 성장의 길을 여는 혁신을 갖춘 위암 진단 제품을 제공하고 있습니다.

Data Bridge Market Research는 중동 및 아프리카 위암 진단 시장이 2030년까지 6,963만 달러 규모에 도달할 것으로 예상하며, 예측 기간 동안 CAGR은 7.4%에 이를 것으로 분석했습니다. 시약 및 소모품은 키트 및 시약에 대한 수요가 증가하고 의료비 지출이 증가함에 따라 스마트 의료 기기에 대한 수요가 가속화되어 시장에서 가장 큰 제품 유형 세그먼트를 차지합니다.

보고서 메트릭

세부

예측 기간

2023년부터 2030년까지

기준 연도

2022

역사적 연도

2021 (2015-2020으로 사용자 정의 가능)

양적 단위

매출은 백만 달러, 볼륨은 단위, 가격은 달러로 표시됨

다루는 세그먼트

제품 유형별(기구, 시약 및 소모품, 서비스), 진단 유형별(확증 검사, 위암 검진 검사/신체 검사), 연령대별(성인, 소아 및 노인), 질병 유형별(장 또는 확산성 선암, 카르시노이드 종양, 위장관 기질 종양(GIST), 위 림프종 및 기타), 병기별(0기, 1기, 2기, 3기), 성별별(남성 및 여성), 샘플 유형별(혈액, 조직, 소변 및 대변), 최종 사용자별(진단 실험실, 병원, 암 연구소, 종양학 전문 병원 및 기타), 유통 채널별(직접 입찰 및 소매 판매)

적용 국가

사우디 아라비아, 남아프리카, UAE, 이스라엘, 이집트 및 기타 중동 및 아프리카

시장 참여자 포함

BIOMÉRIEUX, Myriad Genetics, Inc., Vela Diagnostics, Abbott, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., Biohit Oyj, DiaSorin S.p.A, Paragon Genomics, Inc., and QIAGEN among others

Market Definition

Stomach cancer is a type of cancer that starts in the stomach and spreads throughout the body. The stomach is a muscular pouch that lies immediately below the ribs in the upper part of the abdomen. The stomach takes in and holds the food we eat before breaking it down and digesting it. Stomach cancer, commonly referred to as gastric cancer, can occur in any section of the stomach. Stomach cancers develop in the major section of the stomach in most parts of the world (stomach body). Various diagnostic tests used for the diagnosis of cancer include prescreening tests, biopsy, biomarkers, imaging tests, PET/CT scans, and ultrasound among others.

Cancer is caused by uncontrolled, abnormal cell proliferation that has the ability to spread and invade other sections of the body. Changes in the gene cause a single cell or a few cells to expand and replicate, which is when cancer begins. This could lead to the growth of a tumor, which is an abnormal mass of tissue. The creation of cancer cells in the stomach lining is known as gastric cancer or stomach cancer. Diet and stomach disorders are both risk factors for gastric cancer.

Middle East and Africa Gastric Cancer Diagnostics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

 Drivers

  • Increase in incidence of gastrointestinal tumors, lymphoma, and adenocarcinoma

According to a report published in Clinical Medicine, gastric cancer is the fifth most common cancer and the fourth leading cause of cancer death worldwide in 2020. In 2020, an estimated 1.1 million cases (720,000 males and 370,000 females) of gastric cancer were diagnosed worldwide. Gastric cancer is responsible for about 1 in every 12 oncological fatalities. Every year, about a million new instances of stomach cancer are diagnosed around the world.

It is projected that the incidence of gastric cancer will rise, due to to aging and increasing population, lifestyle, and socioeconomic change. Striking variations in race, sociocultural norms, behaviors, and dietary trends are reflected in the burden and distribution of cancer in different regions across the globe.

Thus, the rising incidence of cancers across the globe is expected to accelerate the demand for gastric cancer diagnostics. Thus the increased incidence rates of gastrointestinal tumors, lymphoma, and adenocarcinoma are expected to drive the growth of the Middle East and Africa gastric cancer diagnostics market.

  • Rise in alcohol consumption and surge in smoking

Epidemiological, clinical, and laboratory evidence point to a behavioral relationship between cigarette smoking and alcohol consumption. The combined use of cigarettes and alcohol poses health concerns in addition to those posed by smoking alone and so represents a severe public health issue that warrants further investigation.

A chemical chain reaction occurs every time a smoker inhales a lit cigarette, producing dozens of hazardous chemicals. Cigarette smoke contains substances that are inhaled through the lips, through the tongue and mouth, down the throat, and into the lungs, producing inflammation and exposing those bodily parts to cancer-causing chemicals.

Thus, the rise in alcohol consumption and surge in smoking is expected to drive the Middle East and Africa gastric cancer market growth.

Opportunity

  • Rise in adoption of automated systems

Cancer is a system and network illness. This indicates that in a cancer cell, certain network-related genes stop working properly. Complex interactions in such gene networks should be addressed in cancer treatment. Artificial intelligence (AI) algorithms, in particular, have been rapidly evolving, which is reflected in oncology's progress.

Machine learning and neural networks are becoming increasingly significant in precision oncology and system medicine. The combination of imaging data with clinical and molecular data opens up a world of possibilities. Radiogenomics, for instance, is a new field focused on multidimensional data processing. It can also benefit from AI advancements.

Thus, the increased adoption of automated systems acts as an opportunity for the growth of this market.

Restraint/Challenge

  • Lack of sufficient financial support from health insurance policies

To achieve their objectives, health systems require financial resources. Human resources, hospital care, and medications are the most expensive aspects of most healthcare systems. In most tropical countries, health care is funded through a combination of government, private (mainly out-of-pocket) spending, and international help.

Healthcare finance remains a key concern for low- and lower-middle-income countries. Many upper-middle-income countries in Latin America, Africa, and Asia have been able to establish health finance arrangements that cover large segments of their populations. These measures enable access to health care while also protecting individuals from catastrophic debt incurred as a result of that access. Finance, on the other hand, is a major obstacle to health care delivery in low-income countries (the bulk of which are in Sub-Saharan Africa).

Thus, the lack of sufficient financial support from health insurance policies acts as a restraint to market's growth.

Recent Developments

  • In October 2022, General Electric Company collaborated with several research institutes such as the University of Cambridge Hospitals, Sophia Genetics, and earlier with Optellum to use imaging data in collaboration with Artificial intelligence. This will help to reduce the diagnosing time of several cancers and help to provide personalized care to patients. This has helped the company to widen its horizons in cancer diagnostics
  • In March 2020, Thermo Fisher Scientific Inc. announced that it would be acquiring QIAGEN, a Netherland-based molecular diagnostics and healthcare company. This acquisition by the company will increase its product portfolio in the market, leading to increased revenue in future

Middle East and Africa Gastric Cancer Diagnostics Market Scope

The Middle East and Africa gastric cancer diagnostics market is segmented into nine notable segments based on product type, diagnostic type, age group, disease type, stage, gender, sample, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

PRODUCT TYPE

  • Instruments
  • Reagents & Consumables
  • Services

On the basis of product type, the market is segmented into instruments, reagents & consumables, and services.

DIAGNOSTIC TYPE

  • Confirmatory Test
  • Gastric Cancer Screening Tests/Physical Exam

On the basis of diagnostics type, the market is segmented into gastric cancer screening tests/physical exam and confirmatory tests.

AGE GROUP

  • Adult
  • Pediatric
  • Geriatrics

On the basis of age group, the market is segmented into adult, pediatric, and geriatrics.

TYPE

  • Intestinal Or Diffuse Adenocarcinoma
  • Carcinoid Tumor
  • Gastrointestinal Stromal Tumor (GIST)
  • Gastric Lymphoma
  • Others

On the basis of type, the market is segmented into intestinal or diffuse adenocarcinoma, carcinoid tumor, gastrointestinal stromal tumor (GIST), gastric lymphoma, and others.

STAGE

  • Stage 0
  • Stage I
  • Stage II
  • Stage III

On the basis of stage, the market is segmented into stage 0, stage I, stage II, and stage III.

GENDER

  • Male
  • Female

On the basis of gender, the market is segmented into male and female.

SAMPLE TYPE

  • Blood
  • Tissue
  • Urine
  • Stool

On the basis of sample type, the market is segmented into blood, tissue, urine, and stool.

END USER​​​​​​​

  • Diagnostic Laboratories
  • Hospitals
  • Cancer Research Institutes
  • Oncology Specialty Clinics
  • Others

On the basis of end users, the market is segmented into diagnostic laboratories, hospitals, cancer research institutes, oncology specialty clinics, and others.

DISTRIBUTION CHANNEL

  • Direct Tenders
  • Retail Sales

On the basis of distribution channel, the market is segmented into direct tender and retail sales.

Middle East and Africa Gastric Cancer Diagnostics Market Regional Analysis/Insights

중동 및 아프리카 위암 진단 시장은 제품 유형, 진단 유형, 연령대, 질병 유형, 단계, 성별, 샘플, 최종 사용자 및 유통 채널을 기준으로 9개의 주요 세그먼트로 구분됩니다. 

이 시장 보고서에서 다루는 국가는 남아프리카공화국, 사우디아라비아, UAE, 이집트, 이스라엘, 그리고 기타 중동 및 아프리카 국가입니다.

2023년에는 남아프리카공화국이 효율적이고 반응성 있는 의료 커뮤니케이션에 대한 수요 증가로 인해 주도적인 역할을 할 것으로 예상됩니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 중동 및 아프리카 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

경쟁 환경 및 위암 진단 시장 점유율 분석

중동 및 아프리카 위암 진단 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, R&D 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 승인, 제품 폭과 범위, 응용 프로그램 우세, 제품 유형 수명선 곡선이 있습니다. 위에 제공된 데이터 포인트는 위암 진단 시장에 대한 회사의 초점과만 관련이 있습니다.

중동 및 아프리카 위암 진단 시장의 주요 기업으로는 BIOMÉRIEUX, Myriad Genetics, Inc., Vela Diagnostics, Abbott, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., Biohit Oyj, DiaSorin SpA, Paragon Genomics, Inc., QIAGEN 등이 있습니다.

 


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET END COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PESTEL'S MODEL

4.2 PORTER'S 5 FORCES

4.3 EPIDEMIOLOGY

4.4 BRAND ANALYSIS

4.5 ROLE OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML): MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET

4.6 INDUSTRY INSIGHTS:

5 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, REGULATORY

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASE IN INCIDENCE OF GASTROINTESTINAL TUMOURS, LYMPHOMA, AND ADENOCARCINOMA

6.1.2 RISE IN ALCOHOL CONSUMPTION AND SURGE IN SMOKING

6.1.3 INCREASE IN THE GERIATRIC POPULATION

6.1.4 RECENT ADVANCEMENTS IN GASTRIC CANCER DIAGNOSTICS PRODUCTS

6.2 RESTRAINTS

6.2.1 HIGH COST OF GASTRIC CANCER DIAGNOSTIC TEST

6.2.2 LACK OF SUFFICIENT FINANCIAL SUPPORT FROM HEALTH INSURANCE POLICIES

6.3 OPPORTUNITIES

6.3.1 RISE IN THE ADOPTION OF AUTOMATED SYSTEMS

6.3.2 INCREASED RESEARCH AND DEVELOPMENT ON CANCER DIAGNOSTICS PRODUCTS

6.3.3 STRATEGIC INITIATIVES BY EMERGING PLAYERS

6.4 CHALLENGES

6.4.1 STRINGENT REGULATIONS AND POLICIES FOR APPROVING THE COMPLICATED NATURE OF RADIATION DEVICES

6.4.2 LIMITATIONS OF RADIATION TESTS

7 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE

7.1 OVERVIEW

7.2 REAGENTS & CONSUMABLES

7.2.1 KITS

7.2.1.1 DNA POLYMERASE KITS

7.2.1.2 PCR KITS

7.2.1.3 NUCLEIC ACID ISOLATION KITS

7.2.1.4 OTHERS

7.2.2 REAGENTS

7.2.2.1 ASSAYS

7.2.2.2 BUFFERS

7.2.2.3 PRIMERS

7.2.2.4 OTHERS

7.3 INSTRUMENTS

7.4 SERVICES

8 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE

8.1 OVERVIEW

8.2 CONFIRMATORY TEST

8.2.1 IMAGING TESTS

8.2.1.1 PET SCAN/CT SCAN

8.2.1.2 CT SCAN

8.2.1.3 ULTRASOUND

8.2.1.4 MRI

8.2.1.5 X-RAY

8.2.2 BIOMARKER

8.2.2.1 DNA BIOMARKER

8.2.2.2 RNA BIOMARKER

8.2.2.3 PROTEIN BIOMARKER

8.2.3 BIOPSY

8.3 GASTRIC CANCER SCREENING TESTS/PHYSICAL EXAM

9 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP

9.1 OVERVIEW

9.2 GERIATRICS

9.3 ADULT

9.4 PEDIATRIC

10 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE

10.1 OVERVIEW

10.2 INTESTINAL OR DIFFUSE ADENOCARCINOMA

10.3 CARCINOID TUMOR

10.4 GASTROINTESTINAL STROMAL TUMOR

10.5 GASTRIC LYMPHOMA

10.6 OTHERS

11 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE

11.1 OVERVIEW

11.2 STAGE I

11.2.1 STAGE IA

11.2.2 STAGE IB

11.3 STAGE II

11.3.1 STAGE IIA

11.3.2 STAGE IIB

11.4 STAGE III

11.4.1 STAGE IIIA

11.4.2 STAGE IIIB

11.4.3 STAGE IIIC

11.5 STAGE 0

12 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER

12.1 OVERVIEW

12.2 MALE

12.3 FEMALE

13 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE

13.1 OVERVIEW

13.2 STOOL

13.3 TISSUE

13.4 BLOOD

13.5 URINE

14 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 DIAGNOSTIC LABORATORIES

14.4 CANCER RESEARCH INSTITUTES

14.5 ONCOLOGY SPECIALTY CLINICS

14.6 OTHERS

15 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 DIRECT TENDERS

15.3 RETAIL SALES

16 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION

16.1 MIDDLE EAST AND AFRICA

16.1.1 SOUTH AFRICA

16.1.2 SAUDI ARABIA

16.1.3 U.A.E

16.1.4 EGYPT

16.1.5 ISRAEL

16.1.6 REST OF MIDDLE EAST AND AFRICA

17 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 F. HOFFMANN-LA ROCHE LTD

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENT

19.2 GENERAL ELECTRIC

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENT

19.3 ABBOTT

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENT

19.4 QIAGEN

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENT

19.5 MYRIAD GENETICS, INC.

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 COMPANY SHARE ANALYSIS

19.5.4 PRODUCT PORTFOLIO

19.5.5 RECENT DEVELOPMENT

19.6 ACON LABORATORIES, INC.

19.6.1 COMPANY SNAPSHOT

19.6.2 PRODUCT PORTFOLIO

19.6.3 RECENT DEVELOPMENT

19.7 ADVACARE PHARMA

19.7.1 COMPANY SNAPSHOT

19.7.2 PRODUCT PORTFOLIO

19.7.3 RECENT DEVELOPMENT

19.8 AGILENT TECHNOLOGIES, INC.

19.8.1 COMPANY SNAPSHOT

19.8.2 REVENUE ANALYSIS

19.8.3 PRODUCT PORTFOLIO

19.8.4 RECENT DEVELOPMENTS

19.9 BIOMÉRIEUX

19.9.1 COMPANY SNAPSHOT

19.9.2 REVENUE ANALYSIS

19.9.3 PRODUCT PORTFOLIO

19.9.4 RECENT DEVELOPMENT

19.1 BIOCEPT, INC.

19.10.1 COMPANY SNAPSHOT

19.10.2 REVENUE ANALYSIS

19.10.3 PRODUCT PORTFOLIO

19.10.4 RECENT DEVELOPMENT

19.11 BIOHIT OYJ

19.11.1 COMPANY SNAPSHOT

19.11.2 REVENUE ANALYSIS

19.11.3 PRODUCT PORTFOLIO

19.11.4 RECENT DEVELOPMENT

19.12 DIASORIN S.P.A

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENT

19.13 ENDOFOTONICS PTE LTD

19.13.1 COMPANY SNAPSHOT

19.13.2 PRODUCT PORTFOLIO

19.13.3 RECENT DEVELOPMENT

19.14 FOUNDATION MEDICINE, INC.

19.14.1 COMPANY SNAPSHOT

19.14.2 PRODUCT PORTFOLIO

19.14.3 RECENT DEVELOPMENTS

19.15 FUJIREBIO (AN H.U. GROUP COMPANY)

19.15.1 COMPANY SNAPSHOT

19.15.2 REVENUE ANALYSIS

19.15.3 PRODUCT PORTFOLIO

19.15.4 RECENT DEVELOPMENT

19.16 MIRXES PTE LTD.

19.16.1 COMPANY SNAPSHOT

19.16.2 PRODUCT PORTFOLIO

19.16.3 RECENT DEVELOPMENT

19.17 PARAGON GENOMICS, INC.

19.17.1 COMPANY SNAPSHOT

19.17.2 PRODUCT PORTFOLIO

19.17.3 RECENT DEVELOPMENTS

19.18 TECO DIAGNOSTICS

19.18.1 COMPANY SNAPSHOT

19.18.2 PRODUCT PORTFOLIO

19.18.3 RECENT DEVELOPMENT

19.19 THERMO FISHER SCIENTIFIC INC.

19.19.1 COMPANY SNAPSHOT

19.19.2 REVENUE ANALYSIS

19.19.3 PRODUCT PORTFOLIO

19.19.4 RECENT DEVELOPMENTS

19.2 VELA DIAGNOSTICS

19.20.1 COMPANY SNAPSHOT

19.20.2 PRODUCT PORTFOLIO

19.20.3 RECENT DEVELOPMENTS

20 QUESTIONNAIRE

21 RELATED REPORTS

표 목록

TABLE 1 APPROVED COMPANION DIAGNOSTIC DEVICE

TABLE 2 THE BELOW-MENTIONED LIST SHOWS THE COST OF PET SCAN FOR CANCER DIAGNOSIS IN DIFFERENT REGIONS ACROSS THE GLOBE-

TABLE 3 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA REAGENT AND CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA INSTRUMENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA SERVICES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA CONFIRMATORY TEST IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA CONFIRMATORY TEST IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA GASTRIC CANCER SCREENING TESTS/PHYSICAL EXAM IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA GERIATRICS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA ADULT IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA PEDIATRIC IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA INTESTINAL OR DIFFUSE ADENOCARCINOMA IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA CARCINOID TUMOR IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA GASTROINTESTINAL STROMAL TUMOR IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA GASTRIC LYMPHOMA IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA OTHERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 MIDDLE EAST & AFRICA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA STAGE 0 IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 34 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 35 MIDDLE EAST & AFRICA MALE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 36 MIDDLE EAST & AFRICA FEMALE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 37 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 38 MIDDLE EAST & AFRICA STOOL IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 39 MIDDLE EAST & AFRICA TISSUE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA BLOOD IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA URINE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA HOSPITALS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 44 MIDDLE EAST & AFRICA DIAGNOSTIC LABORATORIES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 45 MIDDLE EAST & AFRICA CANCER RESEARCH INSTITUTES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 46 MIDDLE EAST & AFRICA ONCOLOGY SPECIALTY CLINICS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 47 MIDDLE EAST & AFRICA OTHERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 48 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 49 MIDDLE EAST & AFRICA DIRECT TENDERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 50 MIDDLE EAST & AFRICA RETAIL SALES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 51 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 52 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 53 MIDDLE EAST & AFRICA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 54 MIDDLE EAST & AFRICA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 55 MIDDLE EAST & AFRICA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 56 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 57 MIDDLE EAST & AFRICA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 58 MIDDLE EAST & AFRICA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 59 MIDDLE EAST & AFRICA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 60 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 61 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 62 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 63 MIDDLE EAST & AFRICA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 64 MIDDLE EAST & AFRICA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 65 MIDDLE EAST & AFRICA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 66 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 67 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 68 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 69 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 70 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 71 SOUTH AFRICA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 72 SOUTH AFRICA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 73 SOUTH AFRICA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 74 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 75 SOUTH AFRICA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 76 SOUTH AFRICA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 77 SOUTH AFRICA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 78 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 79 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 80 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 81 SOUTH AFRICA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 82 SOUTH AFRICA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 83 SOUTH AFRICA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 84 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 85 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 86 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 87 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 88 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 89 SAUDI ARABIA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 90 SAUDI ARABIA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 91 SAUDI ARABIA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 92 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 93 SAUDI ARABIA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 94 SAUDI ARABIA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 95 SAUDI ARABIA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 96 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 97 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 98 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 99 SAUDI ARABIA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 100 SAUDI ARABIA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 101 SAUDI ARABIA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 102 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 103 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 104 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 105 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 106 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 107 U.A.E REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 108 U.A.E KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 109 U.A.E REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 110 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 111 U.A.E CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 112 U.A.E IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 113 U.A.E BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 114 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 115 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 116 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 117 U.A.E STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 118 U.A.E STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 119 U.A.E STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 120 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 121 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 122 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 123 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 124 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 125 EGYPT REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 126 EGYPT KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 127 EGYPT REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 128 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 129 EGYPT CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 130 EGYPT IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 131 EGYPT BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 132 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 133 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 134 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 135 EGYPT STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 136 EGYPT STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 137 EGYPT STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 138 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 139 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 140 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 141 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 142 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 143 ISRAEL REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 144 ISRAEL KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 145 ISRAEL REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 146 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 147 ISRAEL CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 148 ISRAEL IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 149 ISRAEL BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 150 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 151 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 152 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 153 ISRAEL STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 154 ISRAEL STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 155 ISRAEL STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 156 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 157 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 158 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 159 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 160 REST OF MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

그림 목록

FIGURE 1 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: MIDDLE EAST & AFRICA VS. REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: MULTIVARIATE MODELLING

FIGURE 7 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: MARKET END COVERAGE GRID

FIGURE 11 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 12 INCREASE IN THE INCIDENCE OF GASTROINTESTINAL TUMORS, LYMPHOMA, AND ADENOCARCINOMA IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030

FIGURE 13 REAGENTS AND CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET IN 2023 & 2030

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES, OF THE MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET

FIGURE 15 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022

FIGURE 16 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)

FIGURE 17 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)

FIGURE 18 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 19 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, 2022

FIGURE 20 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, 2023-2030 (USD MILLION)

FIGURE 21 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, CAGR (2023-2030)

FIGURE 22 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, LIFELINE CURVE

FIGURE 23 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2022

FIGURE 24 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)

FIGURE 25 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030)

FIGURE 26 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 27 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, 2022

FIGURE 28 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, 2023-2030 (USD MILLION)

FIGURE 29 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, CAGR (2023-2030)

FIGURE 30 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 31 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, 2022

FIGURE 32 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, 2023-2030 (USD MILLION)

FIGURE 33 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, CAGR (2023-2030)

FIGURE 34 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, LIFELINE CURVE

FIGURE 35 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, 2022

FIGURE 36 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION)

FIGURE 37 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030)

FIGURE 38 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE

FIGURE 39 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2022

FIGURE 40 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2023-2030 (USD MILLION)

FIGURE 41 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, CAGR (2023-2030)

FIGURE 42 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, LIFELINE CURVE

FIGURE 43 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, 2022

FIGURE 44 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 45 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 46 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE

FIGURE 47 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 48 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 49 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 50 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 51 MIDDLE EAST AND AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)

FIGURE 52 MIDDLE EAST AND AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)

FIGURE 53 MIDDLE EAST AND AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 54 MIDDLE EAST AND AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 55 MIDDLE EAST AND AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030)

FIGURE 56 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The Middle East and Africa Gastric Cancer Diagnostics Market is projected to grow at a CAGR of 7.4% during the forecast period by 2030.
The future market value of the Middle East and Africa Gastric Cancer Diagnostics Market is expected to reach USD 69.63 million by 2030.
The major players in the Middle East and Africa Gastric Cancer Diagnostics Market are BIOMÉRIEUX, Myriad Genetics, Inc., Vela Diagnostics, Abbott, Fujirebio (An H.U. Group company), Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., etc.
The countries covered in the Middle East and Africa Gastric Cancer Diagnostics Market are Saudi Arabia, South Africa, U.A.E, Israel, Egypt, and rest of Middle East and Africa.